Skip to main navigation Skip to search Skip to main content

A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease

  • Nadine A. Tatton*
  • , A. Maclean-Fraser
  • , William G. Tatton
  • , Daniel P. Perl
  • , C. Warren Olanow
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

198 Scopus citations

Abstract

In situ end-labeling (ISEL) has become a widely used method to determine whether cells die via apoptosis by detecting double-stranded DNA breaks that are the result of endonuclease digestion. The enzyme terminal deoxynucleotidyl transferase can be used to label the digested 3'-OH ends of DNA with biotin-, digoxigenin-, or fluorescent probe-conjugated nucleotides. However, both single-stranded and double-stranded DNA breaks can be labeled by this method and therefore ISEL cannot unequivocally demonstrate apoptosis when used alone. We have developed a fluorescent double-labeling method using ISEL combined with the cyanine dye YOYO-1 that binds to DNA. When combined with confocal laser microscopy and deconvolution analysis, YOYO-1 can demonstrate the presence or absence of nuclear chromatin condensation and thus confirm that ISEL-positive nuclei are indeed apoptotic. Preliminary findings indicate that dopaminergic neurons in the substantia nigra compacta die via apoptosis in Parkinson's disease.

Original languageEnglish
Pages (from-to)S142-S148
JournalAnnals of Neurology
Volume44
Issue number3 SUPPL. 1
DOIs
StatePublished - Sep 1998

Fingerprint

Dive into the research topics of 'A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease'. Together they form a unique fingerprint.

Cite this